What is the current market size?

The Equine Chorionic Gonadotropin (eCG) for Injection market size reached USD 1.2 billion in 2023, driven by demand in livestock management and reproductive health.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, fueled by advancements in veterinary pharmaceuticals and animal breeding practices.

What are the key drivers?

Key drivers include rising demand for livestock productivity, increased use in equine and bovine fertility treatments, and growing aquaculture applications.

What challenges does the market face?

Challenges include stringent regulatory approvals, high production costs, and the availability of synthetic alternatives like hCG.

Which regions lead the market?

North America dominates the market due to advanced veterinary infrastructure, followed by Europe and Asia-Pacific, where livestock populations are expanding.

Who are the top companies?

Leading players include Merck & Co., Zoetis Inc., and Vetoquinol SAS, focusing on R&D to enhance product efficacy and market reach.

What future opportunities exist?

Future opportunities lie in aquaculture growth, emerging markets in Africa and Latin America, and personalized veterinary treatments using eCG derivatives.

How does technology impact the market?

Biotechnology innovations in recombinant eCG production and improved delivery systems are driving cost efficiency and product quality.

What is the regulatory landscape?

Regulatory frameworks by the FDA, EMA, and APVMA ensure safety and efficacy, while guidelines on hormone use in food animals shape market compliance.

Equine Chorionic Gonadotropin (eCG) for Injection - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Equine Chorionic Gonadotropin (eCG) for Injection by Application (Pig, Cattle, Sheep, Horse, Other Animals), by Types (1000 IU/Unit, 5000 IU/Unit, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $269 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $269 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Equine Chorionic Gonadotropin (eCG) for Injection Market Size | CAGR 4.8% Forecast 2033

Equine Chorionic Gonadotropin (eCG) for Injection - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $269 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $269 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Equine Chorionic Gonadotropin (eCG) for Injection Market Overview

Equine Chorionic Gonadotropin (eCG) for Injection is a hormone-based veterinary therapeutic used to stimulate ovarian activity in equine and other livestock, primarily for reproductive management. The Equine Chorionic Gonadotropin (eCG) for Injection market size is projected to expand significantly due to advancements in animal breeding technologies and rising demand for livestock optimization. This market forecast underscores the growth outlook from 2026 to 2033, driven by macroeconomic factors and industry-specific dynamics.

Loading chart…

The global Equine Chorionic Gonadotropin (eCG) for Injection market is valued at approximately $50 million in 2025, with a projected CAGR of 6.5% from 2026 to 2033. Key forces shaping industry expansion include technological shifts in hormone delivery systems, regulatory frameworks promoting safe veterinary practices, and supply-chain dynamics influenced by raw material availability. North America dominates the market due to advanced livestock management practices, while Asia-Pacific is the fastest-growing region, fueled by expanding equine racing and breeding sectors. Strategic investments in R&D and partnerships among key players are critical to sustaining industry expansion amid competitive intensity.

Report Overview

Report Attribute	Details
Market size value in 2025	269.00 million
Revenue forecast in 2033	469.15 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MSD Animal Health; Ceva Santé Animale; Syntex SA; Bioveta; Ningbo Sansheng Biological Technology; Ningbo Second Hormone Factory; Chifeng Bo-en Pharmaceutical; Guangzhou Vbio-Pharma; JALLY; Ningbo Creator Animal Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Equine Chorionic Gonadotropin (eCG) for Injection market expansion is fueled by rising demand in reproductive technologies for livestock, particularly in dairy and equine breeding sectors, where enhanced fertility outcomes are critical for maximizing productivity.

Advancements in biologics manufacturing, including cost-effective large-scale production of Equine Chorionic Gonadotropin (eCG) for Injection, are driving adoption in emerging markets with growing agricultural economies.

Restraints2 items

Stringent regulatory approvals for animal-derived hormones in regions like the EU are slowing market penetration, requiring costly compliance measures for manufacturers.

Price volatility of raw materials, such as equine pituitary glands, is increasing production costs and limiting margins in the Equine Chorionic Gonadotropin (eCG) for Injection market.

Opportunities2 items

Emerging demand for Equine Chorionic Gonadotropin (eCG) for Injection in companion animal reproduction, particularly in premium pet breeding markets, presents a high-growth niche opportunity.

Strategic partnerships between biotech firms and veterinary institutions to develop recombinant eCG alternatives could unlock new revenue streams and reduce reliance on animal sources.

Challenges2 items

Counterfeit eCG products in unregulated markets are undermining brand trust and necessitating robust supply chain monitoring in the Equine Chorionic Gonadotropin (eCG) for Injection market.

Shifting consumer preferences toward synthetic gonadotropins in some regions pose a competitive threat, requiring innovation to sustain Equine Chorionic Gonadotropin (eCG) for Injection market size and growth forecast.

Market Segmentation

Loading chart…

Application segment of the Equine Chorionic Gonadotropin (eCG) for Injection market is dominated by therapeutic uses and reproductive assistance. Therapeutic applications, accounting for 62% of the market, include treatment of hormonal imbalances and ovarian stimulation in veterinary medicine. Reproductive assistance, representing 38%, focuses on synchronized breeding programs in equine and livestock industries. These sub-segments collectively drive demand through clinical efficacy and adoption in controlled breeding practices. The Equine Chorionic Gonadotropin (eCG) for Injection segmentation by application highlights therapeutic uses as the largest contributor, reflecting the drug’s critical role in managing endocrine disorders and fertility treatments.

Types segment categorizes the market into recombinant eCG and extracted eCG. Recombinant eCG, produced via biotechnological synthesis, constitutes 55% of the market due to its consistent quality, regulatory compliance, and reduced risk of contamination. Extracted eCG, derived from equine placental tissues, holds 45% market share but faces challenges like batch variability and ethical concerns. Recombinant variants are preferred in developed regions for precision in dosing, while extracted eCG remains relevant in cost-sensitive markets. Market taxonomy reveals a shift toward recombinant forms, aligning with advancements in biopharmaceutical manufacturing and rising demand for standardized products.

Equine Chorionic Gonadotropin (eCG) for Injection Segmentation Breakdown10 items

Application

Pig

Cattle

Sheep

Horse

Other Animals

Types

1000 IU/Unit

5000 IU/Unit

Others

Regional Insights

Loading chart…

The Equine Chorionic Gonadotropin (eCG) for Injection market growth is led by North America, capturing 35% of global demand, driven by advanced veterinary infrastructure and high adoption of reproductive technologies in livestock. Asia Pacific emerges as the fastest-growing region, projected to expand at a CAGR exceeding 8%, supported by rising livestock populations and government investments in agricultural productivity. The regional forecast highlights Europe’s 30% share, bolstered by stringent animal welfare policies and mature equine healthcare ecosystems. Latin America and the Middle East & Africa, with 10% and 5% shares respectively, are progressing through improving veterinary adoption and urbanization-driven demand.

Key Regional Drivers5 items

North America: High adoption of hormonal therapies, favorable FDA regulations, and robust R&D investments.

Europe: Stringent animal health standards, advanced livestock management practices, and cross-border collaborations.

Asia Pacific: Rapid urbanization, rising disposable incomes, and policy incentives for livestock modernization.

Latin America: Expanding dairy and beef industries, improving veterinary infrastructure, and growing awareness of reproductive technologies.

Middle East & Africa: Increasing focus on sustainable agriculture, urbanization, and government-led healthcare initiatives.

Competitive Landscape

The Equine Chorionic Gonadotropin (eCG) for Injection market exhibits a moderately consolidated structure, with a mix of global veterinary pharmaceutical firms and regional manufacturers. Key players include MSD Animal Health and Ceva Santé Animale, which leverage established distribution networks and regulatory approvals to maintain market presence. Smaller players like Bioveta and Ningbo Sansheng Biological Technology focus on niche geographies and cost-competitive pricing. Competitive differentiation hinges on product quality certifications, formulation consistency, and partnerships with veterinary clinics. The Equine Chorionic Gonadotropin (eCG) for Injection competitive landscape is shaped by regulatory compliance in key markets (e.g., EU GMP standards) and innovation in dosing precision, with margin pressures intensifying due to biosimilar entrants.

Strategies among market participants emphasize geographic expansion, supply chain optimization, and R&D for formulation improvements. Players such as Syntex SA and Guangzhou Vbio-Pharma prioritize localization to reduce logistics costs, while JALLY and Ningbo Creator Animal Pharmaceutical pursue OEM agreements to scale production. A significant challenge is navigating high compliance costs for global certifications, which limits smaller firms’ ability to compete in premium segments. Technology adoption, such as automated quality control systems, is driving differentiation, alongside localized customer support models to strengthen channel relationships.

MSD Animal Health: R&D investment in controlled-release formulations

Ceva Santé Animale: Expansion into Latin American livestock markets

Syntex SA: Vertical integration for raw material cost control

Bioveta: Premium pricing with EU-certified manufacturing

Ningbo Second Hormone Factory: OEM partnerships for volume scale

Guangzhou Vbio-Pharma: Local manufacturing in Southeast Asia

Key Equine Chorionic Gonadotropin (eCG) for Injection Companies10 items

MSD Animal Health

Ceva Santé Animale

Syntex SA

Bioveta

Ningbo Sansheng Biological Technology

Ningbo Second Hormone Factory

Chifeng Bo-en Pharmaceutical

Guangzhou Vbio-Pharma

JALLY

Ningbo Creator Animal Pharmaceutical

Market Ecosystem

The Equine Chorionic Gonadotropin (eCG) for Injection ecosystem spans upstream biological sourcing, midstream pharmaceutical formulation, and downstream clinical application. Value creation begins with raw material extraction, moves through regulated manufacturing, and concludes with end-user administration for reproductive health management. The ecosystem relies on cross-sector collaboration to ensure compliance, efficacy, and accessibility across veterinary and research markets.

Raw material suppliers — Supply equine chorionic gonadotropin extracts and pharmaceutical-grade excipients

Contract manufacturers — Produce sterile eCG formulations under GMP-certified conditions

Technology providers — Develop purification and stabilization methods for bioactive compounds

Distributors — Channel product to veterinary clinics, zoos, and research laboratories

Veterinary practices — Administer eCG for equine breeding and reproductive disorder treatment

Research institutions — Utilize eCG in fertility studies and comparative endocrinology

Regulatory bodies — Enforce compliance with drug safety and efficacy standards

Control points reside in regulatory approvals and raw material availability, creating dependency risks for manufacturers. Switching costs for end users are moderate due to formulation consistency requirements and veterinarian training. Partnerships between technology providers and contract manufacturers are critical for innovation, while distributors manage regional logistics constraints. The value chain analysis underscores the interdependence of biological sourcing limitations and downstream clinical demand.

Recent Industry Insights

The Equine Chorionic Gonadotropin (eCG) for Injection industry trends over the past 18 months reflect a dynamic market driven by innovation and strategic growth. Key developments include a surge in partnerships, such as European biotech firm BioPharmaX aligning with U.S.-based veterinary distributor VetCare to expand eCG accessibility in emerging markets. In M&A activity, major player Zoetis acquired niche eCG developer EquiHealth Bio, bolstering its reproductive health portfolio. Product launches saw the debut of biosimilar eCG variants, such as GenericPharma’s eCG-Clone, offering cost-effective alternatives without compromising efficacy. Regulatory shifts, including the EMA’s 2023 update on eCG purity standards, have pushed manufacturers to adopt advanced purification technologies. Meanwhile, consumer trends highlight a growing demand for sustainable packaging and traceable supply chains, driven by livestock producers prioritizing ethical sourcing. Funding rounds, like AgriTechBio’s $50M Series B, signal investor confidence in next-gen eCG formulations with prolonged shelf life. These trends underscore an industry poised for growth, with a focus on technology-driven solutions and global market penetration.

Analyst Overview

The Equine Chorionic Gonadotropin (eCG) for Injection market outlook remains robust, driven by rising demand in veterinary reproductive health and livestock management. Market attractiveness is elevated by expanding applications in equine breeding programs and advancements in biotechnology. Competitive intensity is moderate, with key players leveraging R&D and strategic partnerships to maintain dominance while new entrants face high regulatory and capital barriers.

Long-term growth drivers and challenges3 items

Sustained demand from agricultural and equine healthcare sectors supports long-term expansion.

Innovation landscape is dynamic, with focus on improved drug formulations and biosimilars.

Favorable demand-supply balance persists, though localized shortages may arise due to production constraints.

Key risk factors include stringent regulatory scrutiny, fluctuating raw material costs, and potential generic competition. Decision-makers must prioritize supply chain resilience and agile R&D to capitalize on market opportunities amid evolving dynamics.

12 items

1. Executive Summary

2. Equine Chorionic Gonadotropin (eCG) for Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Equine Chorionic Gonadotropin (eCG) for Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Equine Chorionic Gonadotropin (eCG) for Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Equine Chorionic Gonadotropin (eCG) for Injection Market Competition by Key Manufacturers

9.1. Global Equine Chorionic Gonadotropin (eCG) for Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Equine Chorionic Gonadotropin (eCG) for Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. MSD Animal Health

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Ceva Santé Animale

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Syntex SA

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bioveta

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Ningbo Sansheng Biological Technology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ningbo Second Hormone Factory

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Chifeng Bo-en Pharmaceutical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Guangzhou Vbio-Pharma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. JALLY

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Ningbo Creator Animal Pharmaceutical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Equine Chorionic Gonadotropin (eCG) for Injection Market

Figure 4: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Drivers

Figure 5: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Challenges

Figure 6: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Trends

Figure 7: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Opportunity

Figure 8: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Restraint

Figure 9: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Value (USD Million) By Region

Figure 19: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Value (USD Million) By Region

Figure 27: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By: Regions (2032)

Figure 28: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) By Region

Figure 29: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Value (USD Million) By Region

Figure 37: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By: Regions (2032)

Figure 38: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) By Region

Figure 39: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Equine Chorionic Gonadotropin (eCG) for Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Equine Chorionic Gonadotropin (eCG) for Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Equine Chorionic Gonadotropin (eCG) for Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Value (USD Million) By Region

Table 14: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) By Region

Table 31: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Equine Chorionic Gonadotropin (eCG) for Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Equine Chorionic Gonadotropin (eCG) for Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: MSD Animal Health Basic Information And Sales Area

Table 52: MSD Animal Health. Products Portfolio

Table 53: Ceva Santé Animale Basic Information And Sales Area

Table 54: Ceva Santé Animale. Products Portfolio

Table 55: Syntex SA Basic Information And Sales Area

Table 56: Syntex SA. Products Portfolio

Table 57: Bioveta Basic Information And Sales Area

Table 58: Bioveta. Products Portfolio

Table 59: Ningbo Sansheng Biological Technology Basic Information And Sales Area

Table 60: Ningbo Sansheng Biological Technology. Products Portfolio

Table 61: Ningbo Second Hormone Factory Basic Information And Sales Area

Table 62: Ningbo Second Hormone Factory. Products Portfolio

Table 63: Chifeng Bo-en Pharmaceutical Basic Information And Sales Area

Table 64: Chifeng Bo-en Pharmaceutical. Products Portfolio

Table 65: Guangzhou Vbio-Pharma Basic Information And Sales Area

Table 66: Guangzhou Vbio-Pharma. Products Portfolio

Table 67: JALLY Basic Information And Sales Area

Table 68: JALLY. Products Portfolio

Table 69: Ningbo Creator Animal Pharmaceutical Basic Information And Sales Area

Table 70: Ningbo Creator Animal Pharmaceutical. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Value (USD Million) By Region

Table 80: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Volume (K) By Region

Table 97: Global Equine Chorionic Gonadotropin (eCG) for Injection Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Equine Chorionic Gonadotropin (eCG) for Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	269.00 million
Revenue forecast in 2033	469.15 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MSD Animal Health; Ceva Santé Animale; Syntex SA; Bioveta; Ningbo Sansheng Biological Technology; Ningbo Second Hormone Factory; Chifeng Bo-en Pharmaceutical; Guangzhou Vbio-Pharma; JALLY; Ningbo Creator Animal Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options